Maki Tanaka

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases.

Hiroya Takeuchi, Anton J. Bilchik, Sukamal Saha et al. · PubMed · 2003 · 234 citations

Medicine, Cancer Biology, Oncology +17

CCL21 Chemokine Regulates Chemokine Receptor CCR7 Bearing Malignant Melanoma Cells

Hiroya Takeuchi, Akihide Fujimoto, Maki Tanaka et al. · Clinical Cancer Research · 2004 · 174 citations

Medicine, Immunology, Oncology +17

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

Yoshiki Hirooka, Hideki Kasuya, Takuya Ishikawa et al. · BMC Cancer · 2018 · 150 citations · Full text

Medicine, Oncology, Chemotherapy +14

Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer

Rin Yamaguchi, Maki Tanaka, Ayako Yano et al. · Human Pathology · 2012 · 146 citations

Medicine, Immunology, Oncology +17